| Revista: | The brazilian journal of infectious diseases |
| Base de datos: | PERIÓDICA |
| Número de sistema: | 000290975 |
| ISSN: | 1413-8670 |
| Autores: | Goncales-Junior, Fernando Lopes1 Vigani, Aline Gonçales, Neiva Barone, Antonio Alci2 Araujo, Evaldo Focaccia, Roberto3 Oliveira, Umbeliana Coelho, Henrique Sergio Moraes4 Paixao, Jacqueline Perez, Renata Lobato, Cirley5 Weirich, Judith Rosa, Heitor6 Borges, Andrelina Vila, Ricardo7 Correa-Giannella, Maria Lucia8 Ferraz, Maria Lucia Gomes9 |
| Instituciones: | 1Universidade Estadual de Campinas, Faculdade de Ciencias Medicas, Campinas, Sao Paulo. Brasil 2Universidade de Sao Paulo, Faculdade de Medicina, Sao Paulo. Brasil 3Instituto Emilio Ribas, Sao Paulo. Brasil 4Universidade Federal do Rio de Janeiro, Rio de Janeiro. Brasil 5Secretaria de Saude do Acre, Rio Branco, Acre. Brasil 6Universidade Federal de Goias, Goiania, Goias. Brasil 7Schering-Plough Brazil, Sao Paulo. Brasil 8Universidade de Sao Paulo, Laboratorio de Investigacao Medica, Sao Paulo. Brasil 9Universidade Federal de Sao Paulo, Sao Paulo. Brasil |
| Año: | 2006 |
| Periodo: | Oct |
| Volumen: | 10 |
| Número: | 5 |
| Paginación: | 311-316 |
| País: | Brasil |
| Idioma: | Inglés |
| Tipo de documento: | Artículo |
| Enfoque: | Experimental |
| Resumen en inglés | Combination therapy with pegylated interferon and ribavirin is considered the new standard therapy for naïve patients with chronic hepatitis C. We evaluated the efficacy and safety of treatment with weight-based peginterferon a-2b (1.5 mg/kg per week) plus ribavirin (800-1,200 mg/day) for 48 weeks in naïve, relapser and non-responder (to previous treatment with interferon plus ribavirin) patients with chronic hepatitis C. Sixty-seven naïve, 26 relapser and 40 non-responder patients were enrolled. The overall sustained virological response (SVR) for the intention-to-treat population was 54% for naïve, 62% for relapser and 38% for non-responder patients. In the naïve subgroup, SVR was significantly higher in patients with the non-1 genotype (67%) compared to those with genotype 1 (45%). In relapsers and non-responders, SVR was, respectively, 69% and 24% in patients with genotype 1 and 43% and 73% in those with genotype non-1. There were no significant differences in SVR rates among the three body weight ranges (< 65 kg, 65-85 kg and > 85 kg) in any of the subgroups. Early virological response (EVR) was reached by 78%, 81% and 58% of naïve, relapser and non-responder patients, respectively, and among those with EVR, 63%, 67% and 61%, respectively, subsequently achieved SVR. All of the non-responder patients who did not have EVR reached SVR. Treatment was discontinued in 13% of the patients, due to loss to follow-up, hematological abnormalities or depression |
| Disciplinas: | Medicina, Química |
| Palabras clave: | Terapéutica y rehabilitación, Bioquímica, Genética, Hepatitis C, Interferón alfa 2b, Genotipos, Terapia |
| Keyword: | Medicine, Chemistry, Therapeutics and rehabilitation, Biochemistry, Hepatitis C, Interferon-alpha 2b, Genotypes, Therapy, Genetics |
| Texto completo: | Texto completo (Ver HTML) |
